Investor Bain Capital Life Sciences Fund II, L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Bain Capital Life Sciences Fund II, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-03-27 13D/A SVRA / Savara Inc. 14,565,457 17,600,621
2024-11-15 13D/A MRSN / Mersana Therapeutics, Inc. 4,041,733 4,968,006
2024-11-14 13G/A XLO / Xilio Therapeutics, Inc. 1,348,682 4,566,817
2024-11-14 13G/A SYRS / Syros Pharmaceuticals, Inc. 2,749,808 2,750,151
2024-04-12 13D/A SVRA / Savara Inc. 14,232,751 14,565,457
2024-03-29 13D/A NUVL / Nuvalent, Inc. 2,400,630 2,400,630
2024-02-13 13G/A SYRS / Syros Pharmaceuticals, Inc. 2,124,694 2,749,808
2023-10-20 13D/A NUVL / Nuvalent, Inc. 2,400,630 2,400,630
2023-07-19 13D/A SVRA / Savara Inc. 11,622,598 14,232,751
2023-02-14 13G/A SYRS / Syros Pharmaceuticals, Inc. 2,124,694
2022-11-03 13D/A NUVL / Nuvalent, Inc. 2,400,630 2,400,630
2022-05-11 13D/A MRSN / Mersana Therapeutics, Inc. 4,041,733 4,041,733
2022-04-14 13D/A MRSN / Mersana Therapeutics, Inc. 3,294,423 4,041,733
2022-02-14 13G/A XLO / Xilio Therapeutics, Inc. 1,348,682 1,348,682
2022-02-14 13G/A SYRS / Syros Pharmaceuticals, Inc. 6,264,420
2022-02-08 13D/A MRSN / Mersana Therapeutics, Inc. 3,294,423 3,294,423
2022-01-03 13D/A MRSN / Mersana Therapeutics, Inc. 3,294,423 3,294,423
2021-11-05 13G XLO / Xilio Therapeutics, Inc. 1,348,682
2021-09-24 13D/A AVIR / Atea Pharmaceuticals, Inc. 4,025,388 3,178,532
2021-09-03 13D/A AVIR / Atea Pharmaceuticals, Inc. 4,025,388
2021-08-04 13D NUVL / Nuvalent, Inc. 2,400,630
2021-03-17 13D/A SVRA / Savara Inc. 5,128,593 11,622,598
2021-01-12 13D/A MRSN / Mersana Therapeutics, Inc. 3,071,566 3,294,423
2020-12-14 13G SYRS / Syros Pharmaceuticals, Inc.
2020-07-20 13G / Therapeutics Acquisition Corp. Class A 891,429
2020-04-17 13D MRSN / Mersana Therapeutics, Inc. 3,071,566
2019-12-30 13D SVRA / Savara Inc. 5,128,593